公开(公告)号：US20200222354A1

公开(公告)日：2020-07-16

申请号：US16826938

申请日：2020-03-23

Applicant: Biogen MA Inc.

Inventor： David Goldman ,  Katherine Dawson ,  Ajay Nirula

IPC: A61K31/225 ,  A61K31/60 ,  A61K45/06 ,  A61K9/20 ,  A61K9/28 ,  A61K31/616 ,  A61K9/48 ,  A61K9/16

Abstract: Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.

公开(公告)号：US20180185319A1

公开(公告)日：2018-07-05

申请号：US15910745

申请日：2018-03-02

Applicant: Biogen MA Inc.

Inventor： David Goldman ,  Katherine Dawson ,  Ajay Nirula

IPC: A61K31/225 ,  A61K45/06 ,  A61K31/60 ,  A61K9/28 ,  A61K9/20 ,  A61K9/48 ,  A61K9/16 ,  A61K31/616

CPC classification number: A61K31/225 ,  A61K9/16 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2833 ,  A61K9/2846 ,  A61K9/4808 ,  A61K31/60 ,  A61K31/616 ,  A61K45/06 ,  A61K2300/00

Abstract: Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.

公开(公告)号：US20180263946A1

公开(公告)日：2018-09-20

申请号：US15988568

申请日：2018-05-24

Applicant: Biogen MA Inc.

Inventor： David Goldman ,  Katherine Dawson ,  Ajay Nirula

IPC: A61K31/225 ,  A61K45/06 ,  A61K31/60 ,  A61K9/28 ,  A61K9/20 ,  A61K9/48 ,  A61K31/616 ,  A61K9/16

CPC classification number: A61K31/225 ,  A61K9/16 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2833 ,  A61K9/2846 ,  A61K9/4808 ,  A61K31/60 ,  A61K31/616 ,  A61K45/06 ,  A61K2300/00

Abstract: Provided herein are compositions containing compounds, or pharmaceutically acceptable salts, that metabolize to monomethyl fumarate with certain pharmacokinetic parameters and methods for treating, prophylaxis, or amelioration of neurodegenerative diseases including multiple sclerosis using such compositions in a subject, wherein if the compositions contain dimethyl fumarate, the total amount of dimethyl fumarate in the compositions ranges from about 43% w/w to about 95% w/w.